Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euo.2023.05.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reply to Riccardo Leni, Andreas Roder, and Hein V. Stroomberg's Letter to the Editor re: Julien Anract, Clément Klein, Ugo Pinar, Morgan Rouprêt, Nicolas Barry Delongchamps, Grégoire Robert. Incidental Prostate Cancer in Patients Undergoing Surgery for Benign Prostatic Hyperplasia: A Predictive Model. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.08.009.
Eur Urol Oncol
December 2024
Department of Urology, CHU de Bordeaux, Université de Bordeaux, Bordeaux, France.
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Eur Urol Oncol
December 2024
Helen Diller Family Cancer Center, University of California-San Francisco, San Francisco, CA, USA. Electronic address:
Enfortumab vedotin (EV) is used as monotherapy or combined with pembrolizumab in advanced urothelial carcinoma (aUC), but biomarker data associated with EV outcomes are limited. We identified 170 patients in the UNITE study who received EV monotherapy and had molecular biomarker data available. Outcomes for groups with and without a particular biomarker were compared using logistic regression (unadjusted) for the objective response rate (ORR), and a log-rank test and Cox proportional-hazard models (CPHMs) for progression-free survival (PFS) and overall survival (OS) from EV initiation.
View Article and Find Full Text PDFPembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
Eur Urol
December 2024
Department of Oncology, University of Debrecen, Debrecen, Hungary.
Article Synopsis
- - Patients with advanced/metastatic urothelial carcinoma who previously responded to or maintained stable disease with pembrolizumab immunotherapy may benefit from retreatment after disease progression, based on a post hoc analysis involving 49 patients from earlier clinical trials.
- - The study found that 41% of these patients achieved an objective response following retreatment, with a notable percentage having had a complete response during the initial treatment, and the median duration of the response was around 14 months.
- - Additionally, the retreatment led to manageable adverse effects, with only 45% experiencing treatment-related events, indicating that pembrolizumab retreatment is a viable and relatively safe option for select patients.
Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life.
Eur Urol
December 2024
Department of Urology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address:
Background And Objective: Treatment burden refers to the overall impact of medical treatments on a patient's well-being and daily life. Our objective is to evaluate the impact of treatment burden on quality of life (QoL) in patients with genitourinary (GU) malignancies, highlighting the importance of patient-reported outcomes (PROs) in clinical trials to inform treatment decisions and improve patient care.
Methods: We conducted a narrative review of clinical trials focused on GU malignancy (prostate, bladder, and kidney) between January 2000 and June 2024, analyzing related PROs and findings regarding treatment burden.
Prospective Analysis of Confocal Laser Endomicroscopy for Assessment of the Resection Bed for Bladder Tumor.
Eur Urol Open Sci
January 2025
Department of Urology, Amsterdam UMC, Amsterdam, The Netherlands.
Background And Objective: Urothelial bladder cancer (UCB) care requires frequent follow-up cystoscopy and surgery. Confocal laser endomicroscopy (CLE), a probe-based optical technique for real-time microscopic evaluation, has shown promising accuracy for grading of UCB. We investigated the diagnostic accuracy of CLE-based assessment of the surgical radicality of the bladder resection bed (RB).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!